Phase 3 EMERALD Trial: Recent Post Hoc Exploratory Analysis of Progression-Free Survival (PFS) Across Subgroups
Along with the Oncology Brothers, Paolo Tarantino, MD, discuss the phase 3 EMERALD study of elacestrant versus standard of care endocrine therapy for ER+, HER2- metastatic breast cancer (MBC). Their conversation focuses on the implications of recently published data demonstrating that elacestrant provides a PFS benefit across clinically meaningful subgroups of patients with ESR1m, ER+, HER2- MBC, including those with endocrine-sensitive disease.
Bardia A, Cortés J, Bidard FC, et al. Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res. 2024;30:4299-4309. https://doi.org/10.1158/1078-0432.CCR-24-1073.
EP. 1: Overview of Phase 3 EMERALD Study of Elacestrant for ER+, HER2–- MBC
November 22nd 2024Along with the Oncology Brothers, Paolo Tarantino, MD, provides an overview of the pPhase 3 EMERALD study, which evaluates the efficacy of elacestrant as a second-line treatment for ER+/HER2–- metastatic breast cancer, particularly in patients with ESR1 mutations.
Watch
EP. 2: Incidence of ESR1 mutations and best practices for testing
November 25th 2024Along with the Oncology Brothers, Paolo Tarantino, MD, discusses how ESR1 mutations (ESR1m) are commonly observed in HR+ breast cancer, particularly after prolonged endocrine therapy, and emphasizes the importance of molecular testing for ESR1m mutations at both the initial diagnosis of metastatic breast cancer (MBC) and at each subsequent progression using liquid biopsy assays.
Watch
EP. 3: Co-occurrence of ESR1m with other alterations
November 25th 2024Along with the Oncology Brothers, Paolo Tarantino, MD, explores how ESR1 mutations (ESR1m) frequently co-occur with other genetic alterations such as PIK3CA, TP53, and HER2-low expression, and discusses the ongoing research into the prognostic significance of these co-occurring mutations in metastatic breast cancer.
Watch
EP. 4: Elacestrant as second-line therapy for ESR1m, endocrine-sensitive disease
November 25th 2024Along with the Oncology Brothers, Paolo Tarantino, MD, elaborates on the San Antonio Breast Cancer Symposium (SABCS) 2022 analysis, which identified the duration of prior CDK4/6 inhibitor (CDK4/6i) therapy as a potential surrogate marker for endocrine sensitivity, and discusses how these findings could help guide the selection of optimal candidates for elacestrant treatment.
Watch
EP. 5: Elacestrant: Clinical Pearls for AE Management
November 25th 2024Along with the Oncology Brothers, Paolo Tarantino, MD, shares insights on what has been learned about proactive monitoring and management of adverse reactions effects (AEs) to elacestrant, emphasizing strategies to help patients remain on therapy while maximizing their quality of life.
Watch
EP. 6: EMERALD subgroup analysis: Elacestrant in endocrine-sensitive disease
November 25th 2024Along with the Oncology Brothers, Paolo Tarantino, MD, discusses the post -hoc subgroup analysis from the EMERALD study (SABCS 2023), which examined outcomes in patients with ESR1 mutations (ESR1m) who had been on CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy for 12 months or longer, and shares her his perspectives on how these findings may influence the use of elacestrant in ER+/HER2–- metastatic breast cancer (MBC) and impact clinical practice for community oncologists.
Watch
EP. 7: Emerging Data on Oral SERDS
November 25th 2024Along with the Oncology Brothers, Paolo Tarantino, MD, discusses ongoing studies investigating novel uses of oral selective estrogen receptor degraders (SERDs), including elacestrant, highlighting trials exploring its combination with other therapies and its potential in different patient populations.
Watch
